For some time in our clinical practice, we have observed that patients with ER-positive metastatic LBC who had relapsed on adjuvant tamoxifen/AIs or had progressed with first-line hormonal therapy tended to show poor responses, and their disease showed faster progression with CDK4/6i [15]. Here, CDK4 is linked to CDH1-related diffuse gastric and lobular breast cancer syndrome.